Cardiff Oncology (CRDF)
(Delayed Data from NSDQ)
$2.29 USD
-0.05 (-2.14%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $2.29 0.00 (0.00%) 7:30 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Cardiff Oncology, Inc. [CRDF]
Reports for Purchase
Showing records 21 - 28 ( 28 total )
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Onvansertib Pancreatic Cancer Phase 2 Trial Starts Enrolling; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Onvansertib; 1Q21 Financial Results; Modulating PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Favorable Yet Preliminary Onvansertib Combo Data in KRAS+ mCRC; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2020 Financial Results; Awaiting Additional Onvansertib Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Onvansertib Optimized Dosing Appears to Sustain Zytiga Efficacy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Despite a Slight ORR Decline, We Await Onvansertib PFS Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to ASCO GI Data; Strong Cash Position; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Cardiff Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Potently Picking off Polo-Like Kinase 1; Initiating at Buy and $27 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R